Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 5,905 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: mRI Clear all

Conditions: MRI Sedation
Interventions: dexmedetomidine, propofol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Month to 16 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 16
States / cities: Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 12 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions: LY3849891, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Chandler, Arizona • Orange, California • Rialto, California + 8 more

Conditions: Non-Compaction Cardiomyopathy
Interventions: Echocardiography, Magnetic resonance imaging (MRI), Computed tomography (CT); Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 3
States / cities: Palo Alto, California • Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Bulimia Nervosa, Binge-Eating Disorder, Obesity, Eating Disorder
Interventions: Negative Affect Task; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 55 Years
Enrollment: 410 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Arthritis, Rheumatoid, Synovitis
Interventions: Methotrexate, Fludarabine; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Neoplasm Female, Early Detection of Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Magnetic Resonance Imaging
Interventions: Enhanced Usual Care, Decision Support; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Glioma
Interventions: Retreatment Rhenium Liposome; Drug
Lead sponsor: Cerenome; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Brain Injury, Extracorporeal Membrane Oxygenation Complication, Hypoxia-Ischemia, Brain, Stroke, Acute
Interventions: Hyperfine; Device
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 0 Days to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Osteopathic Manipulative Treatment (OMT) Effects on Cerebrospinal Fluid (CSF) Dynamics
Interventions: Osteopathic Manipulative Treatment (OMT); Other
Lead sponsor: Edward Via Virginia College of Osteopathic Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Disorder of Nipple, Breast Neoplasms
Interventions: MRI; Device
Lead sponsor: Duke University; Other
Eligibility: 22 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Marijuana, THC, Cannabis
Interventions: Marijuana, Hash, THC, or Grass, Placebo; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib, Adalimumab, Placebo of Fostamatinib, Placebo of Adalimumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Glendale, Arizona • Paradise Valley, Arizona • Phoenix, Arizona + 3 more

Conditions: Adult Ovarian Granulosa Cell Tumor
Interventions: Biospecimen Collection, Chest Radiography, Computed Tomography, Darolutamide, Exemestane, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 66
States / cities: Los Angeles, California • Newark, Delaware • Boise, Idaho + 55 more

Conditions: Cholesterol; Lipidosis
Interventions: Rosuvastatin 10mg; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Human Development
Interventions: MRI; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 30 Weeks to 45 Weeks
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neuroblastoma, Pheochromocytoma, Paraganglioma
Interventions: 18F-mFBG; Drug
Lead sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC); Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biospecimen Collection, Copper Cu 64-DOTA-A2DM, Positron Emission Tomography, Radioconjugate; Procedure · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Stroke, Intracranial Atherosclerosis
Interventions: Ferumoxytol Injectable Product; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Movement Disorders
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 8 Years and older
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cerebral Amyloid Angiopathy
Interventions: Ponezumab, placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 7
States / cities: Los Angeles, California • Boston, Massachusetts • Charlestown, Massachusetts + 2 more

Conditions: Tethered Cord, Chiari I Malformation
Interventions: MRI; Procedure
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Anxiety, Social Anxiety Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions: Functional magnetic resonance imaging (fMRI) with Veritable-NF, fMRI with Sham-NF; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 24 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Cancer
Interventions: MRI UroNav fusion biopsy; Procedure
Lead sponsor: Kaiser Permanente; Other
Eligibility: 30 Years to 79 Years · Male only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Los Angeles, California • Riverside, California

Conditions: Gastrointestinal Cancer, Lung Cancer, Advanced Cancer
Interventions: Specialty Palliative Care; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Search by objective public record fields.

Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

International Consortium for Multimodality Phenotyping in Adults With Non-compaction

Effects of Negative Affect in Individuals With Binge Eating Episodes

Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy

The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

ECMO ABI Detection With Hyperfine

Exploring How Osteopathic Manipulative Treatment May Affect Spinal Fluid Flow: An MRI Study

Diagnostic Utility of MRI in Female Patients With Nipple Discharge: A Prospective Trial

THC Memory & Reward Learning Pilot

Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Liver Adiposity Effects on Pediatric Statin

Characterization of the Functional and Structural Development of the Human Neonatal Brain From 30 Wks to 45 Wks ga

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer

Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRI

Neurophysiological Studies in Patients With Paroxysmal Hyperkinetic Movement Disorders

Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy

Magnetic Resonance Imaging of the Spine

Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4

Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy

The Science of the Art of Palliative Care